Professional Knowledge Marketplace for AI-Resistant Expertise
C5/10June 12, 2026
WhatA vetted marketplace connecting businesses with human experts specifically for tasks where AI fails dangerously — safety-critical translations, code architecture reviews, regulatory compliance — with transparent AI-vs-human quality guarantees.
SignalMultiple commenters describe a growing Dunning-Kruger problem where people overestimate AI capabilities in domains they don't understand, while simultaneously the market for genuinely skilled human work is shrinking even though the need hasn't disappeared — it's just being incorrectly served by AI.
Why NowThe commoditization of AI-adequate work is creating market failure for high-stakes human expertise precisely when that expertise is most needed as a check on AI output.
MarketEnterprises in regulated industries needing certified human review. Competes with traditional freelance platforms (Upwork, Fiverr) but differentiated by quality certification and liability coverage. Niche but high-value — think $500-5000 per engagement, not $50.
MoatCurated expert network with track records and domain-specific quality scores creates two-sided network effects — best experts attract best clients, which attracts more experts.
CRISPR Delivery Platform for Solid Tumor TherapeuticsP7/10A biotech company focused specifically on solving the delivery problem for CRISPR-based cancer therapies, developing novel lipid nanoparticle or viral vector systems that can efficiently transport CRISPR payloads to solid tumors in vivo.
CRISPR Cancer Diagnostics for Undruggable MutationsP6/10A diagnostic platform that profiles patients' tumors for the specific genomic amplifications and mutations that CRISPR-shredding approaches can target, enabling oncologists to match patients to emerging CRISPR therapies.
Biotech Translation Tracker for Informed InvestorsC5/10A platform that tracks the real progress of preclinical and clinical-stage biotech breakthroughs — from lab results through delivery challenges, trial phases, and regulatory milestones — giving investors and patients an honest, hype-free assessment of how close therapies actually are to market.
Viral Vector Therapy Development Platform as ServiceC6/10A contract development platform that helps biotech startups and academic labs design, optimize, and manufacture viral vector (AAV/lentivirus) delivery systems for gene therapies, positioning as the picks-and-shovels play in gene therapy.
Automated Cost Guardrails for AI Agent OperationsP7/10A middleware layer that sits between AI agents and cloud/API services, enforcing hard spending limits, rate controls, and anomaly detection before any resource is consumed.
Prepaid Spending Caps for Cloud and API ServicesC6/10A financial wrapper service that lets developers provision hard-capped, prepaid budgets for cloud and API usage — once the balance hits zero, all calls stop instantly.